United Therapeutics Corporation $UTHR Shares Sold by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. lessened its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 30.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 142,292 shares of the biotechnology company’s stock after selling 63,490 shares during the quarter. Epoch Investment Partners Inc.’s holdings in United Therapeutics were worth $69,332,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Torren Management LLC acquired a new position in shares of United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management increased its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC increased its stake in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. increased its stake in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics during the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $545.83, for a total value of $5,185,385.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,113,210.79. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $549.29, for a total transaction of $5,492,900.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,368,398.04. This represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 634,984 shares of company stock worth $358,175,202. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $545.96 on Friday. The stock has a market capitalization of $23.17 billion, a price-to-earnings ratio of 20.15, a PEG ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The company has a 50 day moving average price of $566.75 and a 200 day moving average price of $521.34.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.63 earnings per share. On average, sell-side analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on UTHR shares. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Finally, Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.